- Indication
- Nausea and Vomiting in pregnancy
- RAG rating
- Red
- Document type
- n/a
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Doxylamine with Pyridoxine (Xonvea®)
Doxylamine/Pyridoxine (Xonvea®)
HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)
Doxylamine/Pyridoxine (Xonvea®) for Nausea and vomiting in pregnancy
RED
Recommended for restricted prescribing by specialist only.
Not recommended for primary care prescribing.
Name generic (trade) Doxylamine/Pyridoxine (Xonvea®)
What it is Doxylamine is a first-generation antihistamine which selectively binds H1 receptors in the brain; pyridoxine (vitamin B6) is a water-soluble vitamin.
Indication Nausea and vomiting in pregnancy
Date decision last revised June 2025
Decision status Final
HWE APC recommendation:
Xonvea® recommended for restricted use as a 3rd line option for women with hyperemesis gravidarum ONLY in secondary care. This follows a minimum 24 hour trial of first line antiemetics (cyclzine/prochloperazine/promethazine/chlorpromazine), then minimum 24 hour trial of second line antiemetics (metoclopramide/domperidone/ondansetron), then a minimum 24 hour trial of combination of first and second line, after which if above has failed, Xonvea® can be trialled.
Ongoing supply will be provided by hospital, ensuring regular review of need for ongoing treatment with advice on gradual reduction/stopping treatment as symptoms improve.
- Version number
- 1.0
- Developed by
- Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
- Approved by
- Hertfordshire & West Essex Area Prescribing Committee
- Date approved / updated
- June 2025
- Review date
- This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
- Superseded version
- n/a